Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma

被引:3
|
作者
She, Ziyu [1 ]
Marzullo, Aldo [2 ]
Destito, Michela [3 ]
Spadea, Maria Francesca [3 ]
Leone, Riccardo [4 ]
Anzalone, Nicoletta [4 ]
Steffanoni, Sara [5 ]
Erbella, Federico [5 ]
Ferreri, Andres J. M. [5 ]
Ferrigno, Giancarlo [1 ]
Calimeri, Teresa [5 ]
De Momi, Elena [1 ]
机构
[1] Politecn Milan, Dept Elect Informat & Bioengn, Milan, Italy
[2] Univ Calabria, Dept Math & Comp Sci, Arcavacata Di Rende, Italy
[3] Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy
[4] IRCCS San Raffaele Sci Inst, Neuroradiol Unit, Milan, Italy
[5] IRCCS San Raffaele Sci Inst, Lymphoma Unit, Milan, Italy
关键词
PCNSL; OS prediction; Deep learning; Model explainability; Grad-CAM; PRIMARY CNS LYMPHOMA;
D O I
10.1007/s11548-023-02886-2
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Purpose Primary central nervous system lymphoma (PCNSL) is a rare, aggressive form of extranodal non-Hodgkin lymphoma. To predict the overall survival (OS) in advance is of utmost importance as it has the potential to aid clinical decision-making. Though radiomics-based machine learning (ML) has demonstrated the promising performance in PCNSL, it demands large amounts of manual feature extraction efforts from magnetic resonance images beforehand. deep learning (DL) overcomes this limitation.Methods In this paper, we tailored the 3D ResNet to predict the OS of patients with PCNSL. To overcome the limitation of data sparsity, we introduced data augmentation and transfer learning, and we evaluated the results using r stratified k-fold cross-validation. To explain the results of our model, gradient-weighted class activation mapping was applied.Results We obtained the best performance (the standard error) on post-contrast T1-weighted (T1Gd)-area under curve = 0.81(0.03), accuracy = 0.87(0.07), precision = 0.88(0.07), recall = 0.88(0.07) and F1-score = 0.87(0.07), while compared with ML-based models on clinical data and radiomics data, respectively, further confirming the stability of our model. Also, we observed that PCNSL is a whole-brain disease and in the cases where the OS is less than 1 year, it is more difficult to distinguish the tumor boundary from the normal part of the brain, which is consistent with the clinical outcome.Conclusions All these findings indicate that T1Gd can improve prognosis predictions of patients with PCNSL. To the best of our knowledge, this is the first time to use DL to explain model patterns in OS classification of patients with PCNSL. Future work would involve collecting more data of patients with PCNSL, or additional retrospective studies on different patient populations with rare diseases, to further promote the clinical role of our model.
引用
收藏
页码:1849 / 1856
页数:8
相关论文
共 50 条
  • [41] Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma
    Tang, Ziqing
    Wu, Geting
    Tan, Fang
    Long, Yang
    Hong, Jidong
    Lyu, Zhiping
    Wei, Rui
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (09) : 760 - 773
  • [42] Identifying Risk Stratification Associated With a Cancer for Overall Survival by Deep Learning-Based CoxPH
    Yang, Cheng-Hong
    Moi, Sin-Hua
    Fu Ou-Yang
    Chuang, Li-Yeh
    Hou, Ming-Feng
    Lin, Yu-Da
    IEEE ACCESS, 2019, 7 : 67708 - 67717
  • [43] Survival among patients with primary central nervous system lymphoma, 1973-2004
    Norden, Andrew D.
    Drappatz, Jan
    Wen, Patrick Y.
    Claus, Elizabeth B.
    JOURNAL OF NEURO-ONCOLOGY, 2011, 101 (03) : 487 - 493
  • [44] SURVIVAL AMONG PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA FROM 1973 TO 2005
    Norden, Andrew
    Drappatz, Jan
    Wen, Patrick
    Claus, Elizabeth
    NEURO-ONCOLOGY, 2009, 11 (05) : 582 - 582
  • [45] Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 US cancer centers
    David, Kevin A. A.
    Sundaram, Suchitra
    Kim, Seo-Hyun
    Vaca, Ryan
    Lin, Yong
    Singer, Samuel
    Malecek, Mary-Kate
    Carter, Jordan
    Zayac, Adam
    Kim, Myung Sun
    Reddy, Nishitha
    Ney, Douglas
    Habib, Alma
    Strouse, Christopher
    Graber, Jerome
    Bachanova, Veronika
    Salman, Sidra
    Vendiola, Jean Alyxa
    Hossain, Nasheed
    Tsang, Mazie
    Major, Ajay
    Bond, David A. A.
    Agrawal, Prashasti
    Mier-Hicks, Angel
    Torka, Pallawi
    Rajakumar, Priya
    Venugopal, Parameswaran
    Berg, Stephanie
    Glantz, Michael
    Goldlust, Samuel A. A.
    Folstad, Matthew
    Kumar, Pallavi
    Ollila, Thomas A. A.
    Cai, Johnny
    Spurgeon, Stephen
    Sieg, Alex
    Cleveland, Joseph
    Chang, Julie
    Epperla, Narendranath
    Karmali, Reem
    Naik, Seema
    Martin, Peter
    Smith, Sonali M. M.
    Rubenstein, James
    Kahl, Brad
    Evens, Andrew M. M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (06) : 900 - 912
  • [46] Serial case report: Primary central nervous system lymphoma in immunocompetent patients
    Rahmawati, D.
    Rachmasari, R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [47] Characterization of Cancer Immune Profiles in Patients with Primary Central Nervous System Lymphoma
    Fei, Fei
    Raniah, Al Amri
    Peker, Deniz
    MODERN PATHOLOGY, 2019, 32
  • [48] Characterization of Cancer Immune Profiles in Patients with Primary Central Nervous System Lymphoma
    Fei, Fei
    Raniah, Al Amri
    Peker, Deniz
    LABORATORY INVESTIGATION, 2019, 99
  • [49] Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma
    Duan, Ling
    He, Yongqi
    Guo, Wenhui
    Du, Yanru
    Yin, Shuo
    Yang, Shoubo
    Dong, Gehong
    Li, Wenbin
    Chen, Feng
    JOURNAL OF NEURO-ONCOLOGY, 2024, 168 (2) : 283 - 298
  • [50] INCREASED OVERALL SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OVER THE PAST 40 YEARS, EXCEPT IN THE ELDERLY
    Mendez, Joe
    Ostrom, Quinn
    Gittleman, Haley
    Kruchko, Carol
    Barnholtz-Sloan, Jill
    DeAngelis, Lisa
    Grommes, Christian
    NEURO-ONCOLOGY, 2017, 19 : 70 - 70